| |
OxyVu-1™
OxyVu-1™ has been in development for nearly
ten years. The device is a non-invasive camera based system which
creates an image or map of hemoglobin oxygenation status with
100 micron resolution. OxyVu-1™ tissue maps provide information
to the physician as to oxygen delivery and oxygen extraction of
the tissue in an anatomically relevant fashion. Our work has demonstrated
changes in the microvasculature of the skin associated with the
severity of complications (foot disease) in diabetic and peripheral
vascular disease patients. The combination of spectral and spatial
information provided by OxyVu-1™ delivers otherwise unavailable
information about local tissue physiology and metabolism that
can be useful in the assessment of local wounds or adequacy of
regional blood flow.
OxyVu-1™’s influence on medical care is unique in
its ability to:
- Provide otherwise unavailable information about tissue structure
and function.
- Deliver early, sub-clinical information not yet apparent to
the naked eye regarding tissue physiology or pathology.
- Be used in real-time to predict outcomes, provide early diagnosis,
direct therapy or identify tissue pathology.
- Transcend the limitations of human vision, allowing the physician
to "see" objective, quantitative data regarding local
tissue abnormalities such as ischemia or cancer, or to detect
local manifestations of systemic processes such as shock.
Both the OxyVu-1™ technology and its clinical applications
have been validated by peer review in more than 35 publications
and presentations at national meetings and been supported by grants
totaling over $4.7 million from the US Army, NIH, ADA, Juvenile
Diabetes Foundation, and NASA.
To date, we have refined and calibrated our OxyVu™ system
in human and animal trials. The collection of over 3,500 images
in clinical studies on over 300 subjects of all ages and skin
colors (both with and without diabetes, peripheral arterial disease
or shock) has enabled us to generate a solid base of clinical
data from which we have been able to design and refine our instrumentation,
measurement technique and analytical methodology. These data have
been published in highly regarded clinical journals such as Lancet
and Diabetes Care and presented at professional annual meetings
such as those sponsored by the American Diabetes Association and
the American Heart Association. |
|
|
